Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Therapeutic Solutions International Inc (OP: TSOI )

0.0007 -0.0001 (-12.50%)
Streaming Delayed Price Updated: 3:40 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 111,952,755
Open 0.0008
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0008
Today's Range 0.0006 - 0.0008
52wk Range 0.0004 - 0.0019
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Therapeutic Solutions International Receives Notice of Allowance for Landmark Patent Covering Cellular Therapy of Lung Diseases
From Therapeutic Solutions International, Inc.
Via Business Wire
Immunology Based Suicide Prevention Company Campbell Neurosciences Announces Appointment of Public Company Veteran Raymond Oliver as Chairman of the Board
From Therapeutic Solutions International, Inc.
Via Business Wire

Performance

YTD
-30.00%
-30.00%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
-46.15%
-46.15%

More News

Read More
Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Announces Landmark Finding Regarding Mechanism of Action of its JadiCell Stem Cell Product
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Files Lawsuit in San Diego Superior Court to Obtain Identities of Certain Individuals or Entities
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Launches Adult Stem Cell Therapy Company Focused on Curing Epilepsy
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Subsidiary Immunotherapy Company Res Nova Bio, Inc. Announces Positive Data on First Four Advanced Cancer Patients Treated with FloraStilbene™
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Announces Formation of ALS Biologics Inc to Commercialize Regenerative Technologies Related to Dreaded Motor Neuron Disease
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International and Campbell Neurosciences Publish on Nutritional Modulation of the Indolamine 2,3 Dioxygenase Pathway as a Non-Toxic Means of Addressing Depression
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Collaborates on Peer-Reviewed Publication on Personalized Immunotherapy for Brain Cancer Using mRNA
From Therapeutic Solutions International, Inc.
Via Business Wire
Res Nova Biologics Announces First Cancer Patient Treated with FloraStilbene™
From Therapeutic Solutions International, Inc.
Via Business Wire
Res Nova Biologics Recruits Abortion Pill Reversal Founder to Scientific Advisory Board
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Announces Paradigm Shifting Immunotherapy Product: Tolerogenic Neutrophils
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Recruits Internationally Renowned Stem Cell Clinician and San Diego Top Doctor to Scientific Advisory Board
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Subsidiary Discloses Potential Solution to Immunotherapy Resistance in Cancer by “Healing Tumor” Before Killing It
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Reports Landmark Advancement in Stem Cell Therapy of Frontotemporal Dementia
From Therapeutic Solutions International, Inc.
Via Business Wire
FloraStilbene™ Demonstrates Synergy with Conventional Chemotherapy and Immunotherapy in Reducing Triple Negative Breast Cancer
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Subsidiary Allogen Biologics Inc. Successfully Manufactures JadiCell Master Cell Bank to Provide Cells for Right to Try Use and Phase III ARDS Clinical Trial
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Prevention Subsidiary Campbell Neurosciences Receives Notice of Allowance on Suicide Prevention Drug Candidate
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Subsidiary Res Nova Bio Inc Discovers New Mechanism of Action for Breast Cancer Immunotherapy Adjuvant FloraStilbene™
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Files for Orphan Drug Designation Use of JadiCell Adult Stem Cells for Treatment of Frontotemporal Dementia
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Files for Orphan Drug Designation Using JadiCell Adult Universal Donor Stem Cells for Treatment of Acute Respiratory Distress Syndrome
From Therapeutic Solutions International
Via Business Wire
Therapeutic Solutions International Launches Subsidiary Company to Commercialize Clinical Data and IND for Treatment of Chronic Traumatic Encephalopathy (CTE) with JadiCell Universal Adult Stem Cells
From Therapeutic Solutions International
Via Business Wire
Therapeutic Solutions International Spin-Off Res Nova Bio Leverages FDA Cleared Tumor Blood Vessel Targeting Technology to Intravenously Deliver Cancer Killing Viruses
From Therapeutic Solutions International
Via Business Wire
Therapeutic Solutions International Spin-Off Res Nova Bio Partners with Cure Stat Rx to Manufacture First in Class Breast Cancer Immunotherapy Product FloraStilbene™
From Therapeutic Solutions International, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.